(MedPage Today) — Updated results from the CARTITUDE-1 trial showed that 33% of patients with heavily pretreated relapsed/refractory multiple myeloma who received ciltacabtagene autoleucel (cilta-cel; Carvykti) were alive and progression free…
Source link : https://www.medpagetoday.com/spotlight/asco-mm/116211
Author :
Publish date : 2025-06-24 13:40:00
Copyright for syndicated content belongs to the linked Source.
